Coronavirus (COVID-19)
Resources for CMS members
MOST RECENT
- Oral COVID-19 medication
March 14, 2022 - Federal CMS guidance on omnibus COVID-19 health care staff vaccination interim final rule
December 30, 2021 - Pfizer Vaccine Shelf-Life Extension
December 21, 2021 - Suggestions for a safe winter holiday season
December 21, 2021 - Increase in vaccine reimbursement for Health First Colorado Medicaid members
December 20, 2021
COVID-19 Resources
- COVID-19 Care protocols & guidance
- COVID-19 Payer Issues
- COVID-19 Physician Wellness
- COVID-19 Financial support
- COVID-19 Telehealth
- COVID-19 PPE/supplies
- COVID-19 Testing
- COVID-19 Workforce issues
- COVID-19 General
Colorado COVID-19 Tracker
Discussion forum
Town Hall Webinars
-
April 21, 2021 Town Hall - Vaccine Access and Legislative Update
(1 hr 22 min) -
January 27, 2021 Town Hall - COVID 19 Listening Session with Leadership
(1 hr 05 min) - January 13, 2021 Town Hall - COVID 19 Vaccine Update
(1 hr 29 min) -
November 19, 2020 Town Hall
(1 hour 27 min)
-
May 20, 2020 Town Hall
(56 min)
-
May 6, 2020 Town Hall
(59 min)
-
April 22, 2020 Town Hall
(1 hr 03 min)
-
April 15, 2020 Town Hall
(1 hr 07 min)
-
April 7, 2020 Town Hall
(1 hr 04 min) | View slides
-
April 1, 2020 Town Hall
(1 hr 02 min)
-
March 25, 2020 Town Hall
(1 hr 29 min)
-
March 18, 2020 Town Hall
(1 hr 35 min)
Virtual Grand Rounds
-
The latest on Omicron and crisis standards of care
December 15, 2021 (1 hr 03 min)
-
Current COVID-19 landscape: Vaccines, mandates and medical ethics
November 10, 2021 (1 hr 39 min)
-
Behavioral Health Task Force
December 2, 2020 (1 hr 39 min)
-
COVID-19 Vaccine Update
November 11, 2020 (1 hr 20 min)
-
Putting Your Patient at the Center of Care: Serious Illness Conversations and Symptom Management in a Time of COVID-19
July 28, 2020 (1 hr 35 min)
-
COVID-19 Treatments
June 10, 2020 (1 hr 31 min)
-
Safe office practices post-COVID-19
May 13, 2020 (1 hr 34 min)
-
COVID-19 Testing
April 29, 2020 (1 hr 29 min)
-
Colorado Crisis Standards of Care
April 13, 2020 (1 hr 35 min)
CDPHE Contact Information
For local public health agencies and healthcare providers only:
- From Monday thru Friday, 8:30 a.m.- 5:00 p.m., please call 303-692-2700.
- For after-hours, holidays, and weekends, please call 303-370-9395.
For general questions about COVID-19:
- Call CO-HELP at 303-389-1687 or 1-877-462-2911.
- You can also email COHELP@RMPDC.org for answers in English.
Latest updates:
-
May 13, 2022: Potentially Significant Drug Interactions, including Contraindicated Drugs (PAXLOVIDTM)
-
March 14, 2022: Oral COVID-19 medication
-
December 29, 2021: Federal CMS guidance on omnibus COVID-19 health care staff vaccination interim final rule
-
December 21, 2021: Pfizer Vaccine Shelf-Life Extension
-
December 20, 2021: Increase in vaccine reimbursement for Health First Colorado Medicaid members
-
December 15, 2021: Virtual Grand Rounds: The latest on Omicron and Crisis Standards of Care
Oral COVID-19 medication
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PAXLOVID for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
- See FDA-authorized Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers, including Prescribing Information available at www.covid19oralrx-hcp.com
- Additional information can also be found at the FDA Emergency Use Authorization website: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization/
- For general product inquiries, contact 877-C19PACK (877-219-7225)
- For medical information, visit www.pfizermedicalinformation.com or call 1-800-438-1985
PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death.
The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.